ArticleResearch and practice in thrombosis and haemostasis2026
Safety and efficacy of direct oral anticoagulants in pediatric oncology patients: real-world data from two quaternary care pediatric centers.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pivotal, phase 3 randomized controlled trials have led to the approval of direct oral anticoagulants (DOACs) for both the management of venous thromboembolism (VTE) and thromboprophylaxis in children. However, few children with cancer-associated thrombosis were enrolled in these trials. There is consequently a need for well-designed observational studies to address current gaps in the pediatric literature. Objectives: The principal objective of this retrospective cohort study was to investigate the safety and efficacy of DOACs for both treatment and prophylaxis of cancer-associated VTE in children. Methods: Prospectively maintained databases at 2 quaternary care children's hospitals were queried for children diagnosed with cancer who received a DOAC for either treatment of VTE or thromboprophylaxis. Medical records of eligible subjects were reviewed for clinical and radiological characteristics. Results: Fifty-one patients (53% female) met eligibility. Forty-seven (92%) patients received DOACs in the setting of a VTE diagnosis (treatment and secondary thromboprophylaxis), while 4 (8%) patients received DOACs for primary thromboprophylaxis. The median age at VTE diagnosis was 14.4 years. Rivaroxaban and apixaban were used in 55% and 45% of patients, respectively. Therapeutic and prophylactic-intensity DOACs were administered in 86% and 78% of patients, respectively, with many patients receiving both. Recurrent/progressive thrombosis occurred in 4 patients (8%). Major and clinically relevant nonmajor bleeding were reported in 6% and 20% of patients, respectively. No deaths were attributed to thrombosis or anticoagulant-related bleeding. Conclusion: Rates of recurrent/progressive thrombosis and clinically relevant bleeding in our cohort of children with cancer-associated thrombosis are higher than those reported in previous studies, highlighting the importance of real-world data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.